NewLimit Unicorn Score: 76/100
South San Francisco, United StatesNewLimit is a biotechnology company focused on developing medicines to extend human healthspan. The company leverages emerging science in cellular aging to create therapies that restore youthful function in old cells, aiming to reverse the cellular degradation that leads to age-related diseases.
Valuation track record
- First screened
- Aug 1, 2026
- Entry valuation
- $3.1B
- Current valuation
- $3.1B
Latest valuation verified from Live re-screening on Aug 1, 2026. Updated quarterly from public funding announcements.
Founders
Brian Armstrong
Co-founder
Jacob Kimmel
Co-founder & CEO
Get the full NewLimit report
Founders deep-dive, traction signals, market thesis, red flags, scoring breakdown and an audio summary, delivered to your inbox.
Frequently asked
What is NewLimit's unicorn score?
NewLimit has a Unicorn Screener score of 76/100, classified as "High Potential". Recommended action: buy.
What is NewLimit's current valuation?
NewLimit's most recently verified valuation is $3.1B, last checked on Aug 1, 2026 (source: Live re-screening).
What sector is NewLimit in?
NewLimit operates in the Biotech sector and is headquartered in South San Francisco, United States.
When was NewLimit first screened?
NewLimit was first screened by Unicorn Screener on Aug 1, 2026, with an entry valuation of $3.1B.